Rocket One Inc. (RKTO) company profile
Close on Nov 18, 2026Market cap $7.53MP/E –Yield –
About Rocket One
Pharmaceutical Preparations, SIC 2834
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new generation therapies designed to address unmet medical needs. The company's development pipeline features drug candidates targeting various conditions across oncology, dermatology, allergy, and neurology. Key pipeline assets include HT-001, a topical formulation for treating skin toxicities resulting from cancer therapies; HT-KIT, a targeted therapeutic for mast cell-derived neoplasms and anaphylaxis; and HT-ALZ, an asset aimed at treating and preventing Alzheimer’s disease and other neuroinflammatory conditions. Additional programs comprise BioLexa for atopic dermatitis, HT-004 for asthma and allergies, and HT-VA for obesity. The company creates these therapies primarily for patients requiring specialized interventions.
The company operates in the United States and has conducted clinical activities in Australia, while securing regulatory authorizations to expand trials into European nations including Spain, Poland, and Hungary. Hoth Therapeutics maintains its principal executive offices in Hoboken, New Jersey.
Summary of the business section of Rocket One's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rocket One Inc.
- Founded
- 2017
- Headquarters
- Hoboken, NJ
- Address
- 720 Monroe Street, Suite E514 07030
- Phone
- (866) 239-7459
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- RKTO
- Former tickers
- HOTH until May 27, 2026
- Exchange
- Nasdaq
- IPO date
- Feb 15, 2019
- Shares outstanding
- 25M, Aug 14, 2026
- Public float
- $15.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Oct 26, 2022
- SEC CIK
- 1711786
- CUSIP
- 44148G204
- ISIN
- US44148G2049
- FIGI
- BBG00H0HZ8S8
- Share class FIGI
- BBG00H0HZ8T7
- EIN
- 82-1553794
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robb Knie | CEO and President, Director | 547,387 |
| David Sarnoff | Director | 25,000 |
| Wayne Linsley | Director | 3,333 |
| Jeff Pavell | Director | 5,075 |
| Christopher Michael Camarra | Director | – |
| Graig Springer | Director | 3,333 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.93M | $1.93M | – | $2 | – |
| FY2024 | $1.23M | $1.23M | – | $1 | – |
| FY2023 | $846.34K | $846.34K | – | $2 | – |
| FY2022 | $1.06M | $1.06M | – | $13 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robb Knie Chief Executive Officer and President | $450.00K | $200.00K | $449.69K | $127.11K | $1.23M | +45% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 15, 2019
- Offer price
- $5.60
- Securities offered
- 1,250,000
- Gross proceeds
- $7.00M
- Exchange
- Nasdaq
- First trading day
- Feb 15, 2019
- First-day close
- $8.53+52.3%
- Lock-up ends (est.)
- Aug 14, 2019
“Per Share Total Initial public offering price $ 5.60 $ 7,000,000 Underwriting discounts and commissions(1)(2) $ 0.392 $ 490,000 Proceeds to us, before expenses $ 5.208 $ 6,510,000 (1) We refer you to “Underwriting (Conflicts of Interest)” beginning on page 89 of this prospectus for additional information regarding”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 26, 2025, we employed a total of 2 full-time employees, 3 employee consultants, and 1 part-time employee.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 11, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 27, 2026 | Name change | Name changed from Hoth Therapeutics, Inc. to Rocket One Inc. |
| May 4, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 16, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Nov 1, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 1, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 4, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 15, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 6, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?